•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Arvinas to Present at Jefferies Global Healthcare Conference
What Arvinas (ARVN) Said on Its Q3 Earnings Call
Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript
What Arvinas (ARVN) Said on Its Q3 Earnings Call
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
Reasons Why Investors Should Consider Betting on Arvinas Stock
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arvinas to Participate in Upcoming Investor Conferences
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know